Recently, the preclinical and Phase I clinical results of TQB2102 (a HER2 bispecific-bispecific ADC), a first-in-class (FIC) new drug independently developed by Chia Tai Tianqing, a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), for the treatment of advanced solid tumors, were published online in Annals of Oncology (impact factor 65.4), the flagship journal of the European Society for Medical Oncology (ESMO). This study, led by the team of Academician Xu Ruihua and Professor Wang Shusen from Sun Yat-sen University Cancer Center, for the first time systematically released the efficacy and safety data of TQB2102 from human clinical studies, and simultaneously disclosed its preclinical research results, confirming the differentiated characteristics of TQB2102 as a bispecific HER2 ADC.

In the field of advanced gastric cancer, CLDN18.2 is the second hot target after HER2 to have its druggability validated, with approximately 38.4% of gastric cancer patients showing high expression of CLDN18.2. On May 22, the CLDN18.2 ADC, Tecotabart Vedotin Monoclonal Antibody for Injection (LM-302), independently developed by LaNova Medicines, a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), and submitted by Shanghai Chia Tai Tianqing, was officially included in the priority review and approval process.

On May 22, Chia Tai Tianqing Pharmaceutical Group, a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), donated 100 million yuan to the China Science and Technology Development Foundation. This move actively implements the national "15th Five-Year Plan" strategic layout, helps build the biopharmaceutical industry into a national emerging pillar industry, and empowers the nation's high-level scientific and technological self-reliance with concrete actions.

On May 21, Sino Biopharmaceutical Limited (SBP Group, 1177.HK) and Boehringer Ingelheim jointly announced that Hernexeos® (generic name in Chinese: zongertinib tablets, generic name in English: zongertinib), which they are co-promoting in mainland China, has been approved by the China National Medical Products Administration (NMPA).

Recently, the world-renowned business magazine Fortune released the "2026 China Environmental, Social, and Governance (ESG) Impact List".

Recently, for Kylo-11 (LPA-siRNA), independently developed by Hygieia Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), the enrollment of all subjects in the China region for a Phase II clinical trial has been successfully completed.

On May 14, the 6th CICC Healthcare Industry Summit 2026 was held in Shanghai. Theresa Tse, Chairwoman of the Board of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), attended and delivered a speech, providing a clear answer for achieving a global breakthrough through a differentiated M&A strategy for local Chinese pharmaceutical companies, combined with a leading advantage across the entire value chain.

On May 12, the inaugural Hong Kong Embodied AI Industry Summit, co-initiated by the Hong Kong Federation of Overseas Chinese Associations and AgileX Robotics, opened in Hong Kong. John Lee Ka-chiu, Chief Executive of the Hong Kong Special Administrative Region; Frederick Ma Si-hang, Chairman of the Hong Kong Trade Development Council; Cheng Cheung Ling, President of Chia Tai Pharmaceutical Group and President of the Hong Kong Federation of Overseas Chinese Associations, attended the event and delivered speeches.

On the morning of May 11, the 6th Asia Summit on Global Health (ASGH), co-hosted by the HKSAR Government and the Hong Kong Trade Development Council, opened at the Hong Kong Convention and Exhibition Centre.

On May 11, Sino Biopharmaceutical Limited (SBP Group, 1177.HK) officially announced that its core enterprise, Chia Tai Tianqing, has entered into an exclusive strategic partnership with GlaxoSmithKline (GSK) to accelerate the marketing process of the first-in-class (FIC) new drug Bepirovirsen in China. Earlier this year, a marketing application for Bepirovirsen was submitted to the Center for Drug Evaluation (CDE) of the National Medical Products Administration and was included in the priority review list.